Compare JILL & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JILL | TMCI |
|---|---|---|
| Founded | 1959 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.5M | 279.6M |
| IPO Year | 2017 | 2021 |
| Metric | JILL | TMCI |
|---|---|---|
| Price | $24.08 | $4.51 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 6 |
| Target Price | ★ $17.00 | $4.77 |
| AVG Volume (30 Days) | 83.8K | ★ 278.2K |
| Earning Date | 06-10-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $596,549,000.00 | $212,690,000.00 |
| Revenue This Year | $2.65 | N/A |
| Revenue Next Year | N/A | $8.18 |
| P/E Ratio | $70.13 | ★ N/A |
| Revenue Growth | N/A | ★ 1.59 |
| 52 Week Low | $10.41 | $1.17 |
| 52 Week High | $23.48 | $7.42 |
| Indicator | JILL | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 77.50 | 43.74 |
| Support Level | $15.40 | $4.25 |
| Resistance Level | N/A | $4.47 |
| Average True Range (ATR) | 1.11 | 0.24 |
| MACD | 0.14 | -0.04 |
| Stochastic Oscillator | 82.25 | 10.53 |
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). J.Jill caters to a distinctive set of women, typically forty-five years and older, offering them various apparel products, footwear, and accessories, comprising shirts, dresses, tops and tees, sweaters, pants and jeans, jewelry, bags, belts, shoes, scarves, etc. The company's operating segments consist of its Retail channels, which derive maximum revenue, and Direct channels. Geographically, the majority of its revenue is derived from the United States.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.